Cited by 526Chromatin Remodeling and CancerPARP inhibition in cancer therapyDNA Repair Mechanisms

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Open access

Shen, Jianfeng, Peng, Yang, Wei, Leizhen, Zhang, Wei, Yang, Lin, Lan, Li, Kapoor, Prabodh, Ju, Zhenlin, Mo, Qianxing, Shih, Ie-Ming, Uray, Ivan P., Wu, Xiangwei, Brown, Powel H., Shen, Xuetong, Mills, Gordon B., Peng, Guang·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-14-0849PMC PMC4497871

Published version of a preprint

Open this paper in CoChat — free account

Abstract

ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors. Significance: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors. Cancer Discov; 5(7); 752–67. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 681

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0849

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798

Show all 61 references

Sorted by citations

Items 301–400 of 526

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Doroshow, D. B., O’Donnell, P. H., Hoffman-Censits, J. H., Gupta, S. V., Vaishampayan, U. N., Heath, E. I., Garcia, P., Zhao, Q., Yu, M., Milowsky, M. I., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00095 · Cited by 11
Poly ADP‐ribose polymerase‐1 as a potential therapeutic target in Merkel cell carcinoma
Ferrarotto, R., Cardnell, R. J., Su, S. Y., Diao, L., Eterovic, A. K., Prieto, V. G., Morrisson, W. H., Wang, J., Kies, M. S., Glisson, B. S., et al. (2018) · Head & Neck · doi:10.1002/hed.25146 · Cited by 11
Defining the Genetics of Basosquamous Carcinoma
Tarapore, E., & Atwood, S. X. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.04.011 · Cited by 11
Elp1 facilitates RAD51-mediated homologous recombination repair via translational regulation
Chen, W.-T., Tseng, H., Jiang, C., Lee, C.-Y., Chi, P., Chen, L., Lo, K., Wang, I., & Lin, F. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00773-z · Cited by 11
Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma
Gorji, L., Brown, Z. J., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15174221 · Cited by 10
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment
Blanc‐Durand, F., Ngoi, N. Y. L., Lim, D. G. S., Ray-Coquard, I. L., & Tan, D. S. P. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102977 · Cited by 11
ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment
Arai, J., Hayakawa, Y., Suzuki, N., Kinoshita, H., Hata, M., Kurokawa, K., Matsushita, Y., Abe, S., Oya, Y., Tsuboi, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113117 · Cited by 10
DNA damage response as a therapeutic target in gynecological cancers
Leary, A. F., Auguste, A., & Mesnage, S. J. L. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000320 · Cited by 10
Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor
Machnicki, M. M., Rzepakowska, A., Janowska, J. I., Pępek, M., Krop, A., Pruszczyk, K., Stawiński, P., Rydzanicz, M., Grzybowski, J., Górnicka, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.768954 · Cited by 10
Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
Chien, W., Tyner, J. W., Gery, S., Zheng, Y., Li, L., Pillai, M. S. G., Nam, C., Bhowmick, N. A., Lin, D., & Koeffler, H. P. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01160-y · Cited by 10
Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening
Zhang, L., Shen, J., Yin, Y., Peng, Y., Wang, L., Hsieh, H.-J., Shen, Q., Brown, P. H., Tao, K., Uray, I. P., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217698942 · Cited by 10
Self-citation
Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
Zheng, E., Włodarczyk, M., Węgiel, A., Osielczak, A., Możdżan, M., Biskup, L., Grochowska, A., Wołyniak, M., Gajewski, D., Porc, M., et al. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1398289 · Cited by 10
Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
Yin, C., Kulasekaran, M., Roy, T., Decker, B. J., Alexander, S., Margolis, M. L., Jha, R. C., Kupfer, G. M., & He, A. R. (2022) · Cancers · doi:10.3390/cancers14102561 · Cited by 9
Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology
Valentini, V., Silvestri, V., Bucalo, A., Conti, G., Karimi, M., Francesco, L. D., Pomati, G., Mezi, S., Cerbelli, B., Pignataro, M. G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1092201 · Cited by 9
The Chromatin Remodeling ComponentArid1aIs a Suppressor of Spontaneous Mammary Tumors in Mice
Kartha, N., Shen, L., Maskin, C. R., Wallace, M. D., & Schimenti, J. C. (2016) · Genetics · doi:10.1534/genetics.115.184879 · Cited by 9
SWI/SNF-deficient cancers of the Gastroenteropancreatic tract: an in-depth review of the literature and pathology
Nowak, K. M., & Chetty, R. (2020) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2020.11.001 · Cited by 9
ARID1A regulates E-cadherin expression in colorectal cancer cells: a promising candidate therapeutic target
Erfani, M., Zamani, M., Hosseini, S. Y., Mostafavi‐Pour, Z., Shafiee, S. M., Saeidnia, M., & Mokarram, P. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06671-9 · Cited by 9
Endometrial Cancer
Li, J. J. X., & Ip, P. P. C. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2022.02.006 · Cited by 10
JNK pathway plays a critical role for expansion of human colorectal cancer in the context of BRG1 suppression
Yoshikawa, T., Fukuda, A., Omatsu, M., Namikawa, M., Sono, M., Fukunaga, Y., Masuda, T., Araki, O., Nagao, M., Ogawa, S., et al. (2022) · Cancer Science · doi:10.1111/cas.15520 · Cited by 9
Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications
Kuhn, E., Gambini, D., Runza, L., Ferrero, S., Scarfone, G., Bulfamante, G., & Ayhan, A. (2024) · Cancers · doi:10.3390/cancers16132458 · Cited by 8
Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer
Zhao, Q., Bai, L., Tan, Y., & Qie, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1435029 · Cited by 9
Controversies in the management of clear cell carcinoma of the uterus and ovary
Sachdeva, M., Blanc‐Durand, F., & Tan, D. S. P. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101681 · Cited by 8
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Yamada, D., Kobayashi, S., Doki, Y., & Eguchi, H. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02761-x · Cited by 8
Targeting base excision repair in precision oncology
Montaldo, N. P., Nilsen, H. L., & Bordin, D. L. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103844 · Cited by 10
Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer
Kim, J. Y., Park, C. K., Noh, S., Cheong, J., Noh, S. H., & Kim, H. (2023) · Gut and Liver · doi:10.5009/gnl220342 · Cited by 8
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Xing, T., Li, L., Rao, X., Zhao, J., Chen, Y., Ju, G., Xu, Y., Gao, X., Dong, G., Xia, X., et al. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-03059-w · Cited by 8
SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study
Chen, I. Y., Ettel, M. G., Bell, P. D., Huber, A. R., Findeis-Hosey, J. J., Wang, W., Hezel, A. F., Dunne, R. F., Drage, M. G., & Agostini‐Vulaj, D. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.01.013 · Cited by 7
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer
Li, W., Huang, Y., Xiao, M., Zhao, J., Du, S., Wang, Z., Hu, S., Yang, L., & Cai, J. (2024) · iScience · doi:10.1016/j.isci.2024.109160 · Cited by 8
Self-citation
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Raupach, E. A., Hegde, A. M., Garcia‐Mansfield, K., Alcantara, M. B., Rose, D. L., Halperin, R. F., Orlando, K. A., Lang, J. D., Sharma, R., David‐Dirgo, V., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-0044 · Cited by 7
Transcription‐Replication Conflicts: Unlocking New Frontiers in Cancer
Bayona‐Feliú, A., & Aguilera, A. (2025) · BioEssays · doi:10.1002/bies.70025 · Cited by 7
A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer
Sadagopan, N., Wang, H., Yin, C., Weinberg, B. A., Noel, M. S., Mukherji, R., Geng, X., Marshall, J. L., & He, A. R. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01009-1 · Cited by 7
ARID1A: gene, protein, and function in endometrial cancer
LaBuda, S. E., Broaddus, R. R., & Gladden, A. B. (2025) · Oncogene · doi:10.1038/s41388-025-03539-1 · Cited by 7
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Fujiwara, S. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad057 · Cited by 7
Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma
Li, S., Meersma, G. J., Kupryjańczyk, J., de Jong, S., & Wisman, G. B. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05311-7 · Cited by 7
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
Zhao, J., Zhu, J., Tang, Y., Zheng, K., & Li, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1463892 · Cited by 7
Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective
Nottegar, A., Veronese, N., Solmi, M., & Luchini, C. (2016) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.100255 · Cited by 7
Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis
Zhao, Q., Cai, Q., Yu, S., Ji, J., Zhu, Z., Yan, C., & Zhang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745120 · Cited by 7
Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex
Huang, S., Chen, K., Ng, K., Lin, I.-C., Chao, Y.-C., Yeh, T., Chuang, H., & Chen, T. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03288-6 · Cited by 7
Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers
Reilly, N. M., Yard, B. D., & Pittman, D. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9500-4_1 · Cited by 9
Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies
Jabbour, S. K., Williams, T. M., Sayan, M., Miller, E. D., Ajani, J. A., Chang, A. C., Coleman, C. N., El-Rifai, W. M., Haddock, M. G., Ilson, D. H., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa195 · Cited by 7
Current challenges to underpinning the genetic basis for cholangiocarcinoma
Cigliano, A., Chen, X., & Calvisi, D. F. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1915128 · Cited by 9
New molecular tumor markers for endometrial cancer.
Numa, F., Umayahara, K., Suehiro, Y., Suminami, Y., Oga, A., Sasaki, K., & Kato, H. (2001) · PubMed · Cited by 7
PARP inhibitors in non-ovarian gynecologic cancers
Fernandes, Í., Chehade, R., & MacKay, H. J. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241255174 · Cited by 6
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer
Burdett, N. L., Willis, M. O., Pandey, A., Fereday, S., AOCS Study Group, Management Group, Bowtell, D. D. L., Chenevix‐Trench, G., Green, A. C., Webb, P. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48153-x · Cited by 6
Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos
Hartley, A., Galbraith, L. C. A., Shaw, R., Tibbo, A. J., Veeratterapillay, R., Wilson, L., Heer, R., Blyth, K., Leung, H. Y., & Ahmad, I. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02944-3 · Cited by 6
Anomalies de la réparation de l’ADN et cancers gynécologiques
Auguste, A., & Leary, A. F. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.09.007 · Cited by 8
Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
Zhao, X., Zhou, J., Dong, L., Zhang, H., & Ye, Y. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000550 · Cited by 6
SWI/SNF Alterations in Squamous Bladder Cancers
Achenbach, F., Rose, M., Ortiz‐Brüchle, N., Seillier, L., Knüchel, R., Weyerer, V., Hartmann, A., Morsch, R., Maurer, A., Ecke, T., et al. (2020) · Genes · doi:10.3390/genes11111368 · Cited by 6
The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling
Jdeed, S., Erdős, E., Bálint, B. L., & Uray, I. P. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0961 · Cited by 6
Self-citation
Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report
Zhao, Y., & Jiang, Y. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s362267 · Cited by 6
The entanglement of DNA damage and pattern recognition receptor signaling
Ha, C. T., Tageldein, M. M., & Harding, S. M. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103595 · Cited by 6
Ovarian Epithelial Carcinogenesis
Zhang, J., Silva, E. G., Sood, A. K., & Liu, J. (2019) · Springer eBooks · doi:10.1007/978-981-13-3019-3_4 · Cited by 6
Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers
Tang, Y., Lin, C., & Lai, C. (2021) · Genes · doi:10.3390/genes12101593 · Cited by 5
Identification and functional characterization of a novel bipartite nuclear localization sequence in ARID1A
Bateman, N. W., Shoji, Y., Conrads, K. A., Stroop, K. D., Hamilton, C. A., Darcy, K. M., Maxwell, G. L., Risinger, J. I., & Conrads, T. P. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.080 · Cited by 6
DNA-damage orchestrates self-renewal and differentiation via reciprocal p53 family and Hippo/Wnt/TGF-β pathway activation in embryonic stem cells
Ye, Y., Xie, W., Wang, X., Tan, S., Yang, L., Ma, Z., Zhu, Z., Chen, X. X., Liu, X., O’Neill, E. E., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05561-0 · Cited by 5
Self-citation
Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.
Li, R., Xiong, G., Zhao, J., & Yang, L. (2022) · PubMed Central · Cited by 5
Self-citation
Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors
Mironova, E., Molinas, S., Pozo, V. D., Bandyopadhyay, A. M., Lai, Z., Kurmashev, D., Schneider, E. L., Santi, D. V., Chen, Y., & Kurmasheva, R. T. (2024) · Cancers · doi:10.3390/cancers16112041 · Cited by 5
Evaluating the efficacy of PARP inhibitor in ARID1A-deficient colorectal cancer: A ex vivo study
Zong, R., Zhou, P., Qin, S., Li, J., Xu, S., Kang, M., & Zhang, Y. (2025) · Cancer Biomarkers · doi:10.1177/18758592251317873 · Cited by 5
Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas
Pikul, J., Machnicki, M. M., Rzepakowska, A., Winiarska, N., Chudy, A., Moskowicz, A., Król, K., Fus, Ł., Kostrzewa, G., & Stokłosa, T. (2025) · BMC Cancer · doi:10.1186/s12885-024-13421-0 · Cited by 6
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
Chelariu-Raicu, A., Molin, G. Z. D., & Coleman, R. L. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001789 · Cited by 5
Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer
Park, S. E., Kim, H. S., Jung, E.-J., Suh, J. H., Min, H., Chi, K., Kim, J. W., Park, J., & Hwang, I. G. (2022) · Journal of Cancer · doi:10.7150/jca.65145 · Cited by 5
Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies
Cathcart, A. M., Smith, H. L., Labrie, M., & Mills, G. B. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2070065 · Cited by 6
Self-citation
Heterogeneous expression of ARID1A in colorectal cancer indicates distinguish immune landscape and efficacy of immunotherapy
Guan, X., Cui, L., Ruan, Y., Fang, L., Dang, T., Zhang, Y., & Liu, C. (2024) · Discover Oncology · doi:10.1007/s12672-024-00955-9 · Cited by 5
Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer
Li, Y., Zhou, Z., Zhang, Y., Jia, D., Wang, D., Reiger, M. C., Creighton, C. J., Nelson, P. S., Corey, E., Morrissey, C. M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03631-6 · Cited by 4
Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies
Zhang, C., Zhu, Y., Ai, L., Wang, J., Yu, S., Wang, Y., Xu, X., Liu, M., Yu, Y., Zhu, M.-X., et al. (2025) · Advanced Science · doi:10.1002/advs.202512074 · Cited by 4
Phosphoproteome landscape of ARID1A and its implications in DNA damage response and breast cancer pathogenesis
Kumar, A. P. K. A., Dcunha, L., Mahin, A., Shivamurthy, P. B., Subair, S., Gopalakrishnan, A. P., Rajeev, A. C., & Raju, R. (2026) · Discover Oncology · doi:10.1007/s12672-025-03408-z · Cited by 4
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer
Li, Q., Zhang, Z., Wang, Y., Peng, X., Fang, Y., Zhang, Y., Chen, L., Huang, T., Yang, Z., Li, C., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3231 · Cited by 4
Self-citation
The hidden architects of the genome: a comprehensive review of R-loops
Yadav, C., Yadav, R., Nanda, S., Ranga, S., & Ahuja, P. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10025-6 · Cited by 4
Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer
Liu, F., Ying, J., Yang, K., Xiong, X., Yang, N., Wang, S., Zhao, W., Zhu, H., Yu, M., Wu, J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114916 · Cited by 4
Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2/4 degraders
Yang, T., Wei, W., Zhang, Q., Chen, X., Xu, K., Su, X., Lin, Y., Gao, J., Wang, N., Cao, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117521 · Cited by 4
Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition
Kuo, T., Hou, Y., Shan, Y., Chen, L., & Hung, W. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70394 · Cited by 4
Synthetic lethality in personalized cancer therapy
Pang, Y. K., Cheng, M., Chen, M., Zhao, K., Yin, Y., Liu, M., Zhang, J., & Zhong, C. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00080-3 · Cited by 4
Genome-Wide CRISPR Screen Identifies KEAP1 Perturbation as a Vulnerability of ARID1A-Deficient Cells
Fournier, L.-A., Kalantari, F., Wells, J. P., Lee, J. S., Trigo‐Gonzalez, G., Moksa, M., Smith, T., White, J., Shanks, A., Wang, S., et al. (2024) · Cancers · doi:10.3390/cancers16172949 · Cited by 4
Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma
Saito, R., Fukushima, M., Sasaki, M., Okamoto, A., & Ogiwara, H. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00850-8 · Cited by 5
ARID1A Governs Genomic Stability and Proliferation in SCLC via c-MYC/PARP1 Suppression Driving Vulnerability to BET Inhibitors
Cao, G., Ma, L., Dai, X., Hou, P., Yao, X., Li, G., Zhang, J., Chen, C., & Lin, W. (2025) · Research · doi:10.34133/research.0908 · Cited by 3
Chromatin remodeling complexes: architects influencing breast cancer progression
Giovani, O., Eckersley, G. S., Jones, H. R., & Nagarajan, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1690350 · Cited by 3
Implications of DNA damage response and immunotherapy in tumor therapy
Li, W., Li, B., Cai, C., Chen, J., Li, Y., Liang, R., & Zhao, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02527-y · Cited by 3
Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings
Willman, G. H., Podder, V., Westin, S. N., Corr, B. R., Coleman, R. L., Pothuri, B., Moore, K. N., & Slomovitz, B. M. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102859 · Cited by 3
ARID1A loss sensitizes colorectal cancer cells to floxuridine
Xiang, C., Wang, Z., Yu, Y., Han, Z., Lu, J., Pan, L., Zhang, X., Wang, Z., He, Y., Wang, K., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101069 · Cited by 4
Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells
Schlosser, R., Krumbach, F., Corrales, E., Andrieux, G., Preisinger, C., Liss, F., Golzmann, A., Boerries, M., Becker, K., Knüchel, R., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70019 · Cited by 3
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
Lecce, C. D., Eccher, S., Simbolo, M., Cocomazzi, A., Piredda, M. L., Caliò, A., Cima, L., Munari, E., Veronese, N., Avancini, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108594 · Cited by 3
Complete remission of endometrial cancer stage IVC treated with multimodality treatment including immunotherapy and maintenance PARP inhibitor – A case report
Chen, Y.-Y., Liu, F., Chiang, Y., & Lai, C. (2025) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2024.12.027 · Cited by 3
The complex genetics of epigenetics in urothelial carcinomas
Frew, I. J., Timmers, H. T. M., Schüle, R., & Gratzke, C. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00386-5 · Cited by 3
A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study
Wang, X., Zhang, L., Zhou, D., Cai, H., Wang, X., & Jiang, X. (2020) · Medicine · doi:10.1097/md.0000000000021948 · Cited by 3
PLK1 inhibition selectively kills ARID1A deficient cells through uncoupling of oxygen consumption from ATP productionPreprint
Srinivas, U. S., Ramachandran, G. K., Wardyn, J. D., Hoppe, M. M., Peng, Y., Lim, S., Lee, M. Y., Peethala, P. C., An, Ö., Shendre, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446664 · Cited by 3
Self-citation
Identification of assembly mode of non-canonical BAF (ncBAF) chromatin remodeling complex core module
Mo, Q., Liu, B., Liu, C., Long, J., & Zhou, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151238 · Cited by 2
Self-citation
Impact of mSWI/SNF epigenetic complexes on ionizing radiotherapy resistance in malignant diseases: A comprehensive view in oncology
Trejo-Villegas, O. A., Pérez‐Cárdenas, E., Magos, F. M., & Ávila‐Moreno, F. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123690 · Cited by 2
Evaluating the ‘ARID’ landscape of SWI/SNF complexes with relevance to cancer
Hore, P., Sarkar, S., & Bashyam, M. D. (2025) · Gene · doi:10.1016/j.gene.2025.149664 · Cited by 4
Inhibition of both SWI/SNF ATPases by BRM014 impairs homologous recombination, sensitizes cells to DNA damage and PARP inhibitors, and activates the cGAS/STING response
Alfano, P., Rocha, F., Dille, A., Kirk, F., Kendall, M., Paul, E., Lyon, M., Ramakrishnan, U., Pendleton, E., & Vélez-Cruz, R. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103884 · Cited by 2
Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma
Urbanova, M., Viol, F., Ruiz-Cañas, L., Koniaris, E., Saksis, R., Batres-Ramos, S., Earl, J., Kataki, A., Buociková, V., Buríková, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218033 · Cited by 2
Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies
Prasopporn, S., Sittithumcharee, G., Chanthercrob, J., Limsrichamrern, S., Hirankitti, A., More-Krong, P., Sathirareuangchai, S., Chaiboonchoe, A., Sampattavanich, S., Okada, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24420-x · Cited by 2
KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?
Krupa, K., Fudalej, M. M., Miski, H., Włoszek, E., Szymczak, M., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17233769 · Cited by 2
Therapeutic opportunities in EBV-positive gastric cancer subtypes
Al-Sattar, H., Owen, R. P., Jaafari, A. M., Saha, A., Ayyappan, K., Ghose, A., Boussios, S., & Adeleke, S. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396619 · Cited by 2
A Review of ARID1A’s Role in Breast Cancer Progression: Context-Dependent Mechanisms and Therapeutic Implications
Shankari, G., Prabhu, D., Sureshan, M., Jeyakanthan, J., & Rajamanikandan, S. (2025) · Cancers · doi:10.3390/cancers18010142 · Cited by 2
Synthetic lethality in cancer: mechanism exploration and therapeutic applications
Zhao, P., Wang, P., Xu, T., Chen, L., Jia, Q., & Li, M. H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02932-x · Cited by 2
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance
Morgera, V., Feola, A., Romano, A., Napoli, M. V., Gabrielli, A., Avvedimento, V. E., Porcellini, A., & Pezone, A. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00779-z · Cited by 3
Molecular convergence in gallbladder cancer: MEK–ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks
Jaiswar, D., & Dixit, M. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04349-5 · Cited by 3
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials
Martín-Romano, P., Daage, L. C., Morel, D., Baldini, C., Verlingue, L., Bahleda, R., Gazzah, A., Champiat, S., Varga, A., Michot, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.014 · Cited by 2
Platinum Sensitivity inIDH1/2Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
Doroshow, D. B., Wei, W., Mehrotra, M., Sia, D., Eder, J. P., Bindra, R. S., Houldsworth, J., LoRusso, P. M., & Walther, Z. (2023) · Cancer Investigation · doi:10.1080/07357907.2023.2242957 · Cited by 2
Homologous Recombination Repair Gene Alterations Are Associated with Tumor Mutational Burden and Survival of Immunotherapy
Ito, M., Kubo, M., Kawaji, H., Otsubo, Y., Kurata, K., Abutani, H., Suyama, M., Oda, Y., Yoshizumi, T., Nakamura, M., et al. (2023) · Cancers · doi:10.3390/cancers15235608 · Cited by 2

Authors: Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., Uray, I. P., Wu, X., Brown, P. H., Shen, X., Mills, G. B., & Peng, G.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
Johns Hopkins University (US)
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author: Peng, Guang
ORCID: Shen, Jianfeng
Peng, Yang
Zhang, Wei
Yang, Lin
Lan, Li
Ju, Zhenlin
Mo, Qianxing
Shih, Ie-Ming
Wu, Xiangwei
Brown, Powel H.
Mills, Gordon B.
Peng, Guang
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-07-01
Volume: 5
Issue: 7
Pages: 752-767
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-14-0849
PMC: PMC4497871
OpenAlex: W2123454509
Cited by: 522
References: 61
Citations by year: 2026: 33 · 2025: 53 · 2024: 59 · 2023: 56 · 2022: 53 · 2021: 71 · 2020: 62 · 2019: 43 · 2018: 36 · 2017: 28 · 2016: 24 · 2015: 3
FWCI: 13.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (CA 016672, P50CA098258, P50-CA83639, R00CA149186, K99CA149186, P50CA083639, P30CA016672, R01CA181663)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords: ARID1A, SWI/SNF complex, DNA damage checkpoint, PARP inhibitors, ATR kinase, DNA double-strand breaks, tumor suppressor, drug sensitivity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Breast Neoplasms, DNA Damage, DNA-Binding Proteins, Female, Humans, Lung Neoplasms, Male, Nuclear Proteins, Transcription Factors, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Mice, DNA Breaks, Double-Stranded, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks